Abbott (NYSE:ABT) announced today that it received FDA clearance for its latest optical coherence tomography (OCT) imaging platform.
Powered by the company’s new Ultreon software, the latest imaging platform combines OCT with artificial intelligence (AI) to provide physicians with an enhanced, comprehensive view of coronary blood flow and blockages to aid in physician decision-making, according to a news release.
The software integrates with Abbott’s new Dragonfly OpStar imaging catheter and PressureWire X guidewire, offering physicians access to several tools for accessing coronary blood flow blockages.
Abbott Park, Ill.-based Abbott launched the OCT platform with Ultreon software in Europe in April.
“As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care,” Abbott CMO & divisional VP of global medical affairs for the company’s vascular business Dr. Nick West said in the release. “AI enables Ultreon software to automatically detect calcium and vessel diameters allowing doctors to put stents exactly where they are needed.”
